# US 11,304,935 B2 · Use of I-BRD9 or derivatives thereof in preparing anti-epileptic drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,304,935 B2
- Document ID: US11304935B2
- Status: Granted
- Kind: B2
- Application number: 16/961,267
- Filed: 2019-09-25
- Published: 2021-03-04
- Granted: 2022-04-19
- Earliest claimed: 2018-12-18
- Assignees: University of South China
- Applicants: University of South China
- Inventors: Wenyu Cao; Yang Xu; Dan Luo; Wei Wan; Jie He; Xiaolin Zhong; Xi Chen; Zhenghai Liu; Jiayu Zeng; Zhen Wang; Hui Yang; Lei Niu; Shishi Luo
- Web page: https://patentgrep.com/patent/US11304935B2

## CPC

- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are methods of using bromodomain-containing protein 9 inhibitor (I-BRD9) or a derivative thereof in preparation of anti-epileptic drugs. The I-BRD9 has significant effects on anticonvulsion, prolonging of convulsion latency, and reduction of seizure level, and can be used for preparing anti-epileptic drug preparations.

## Claims

### Claim 1

A method for treating epilepsy, comprising administering I-BRD9 to a subject in need thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the I-BRD9 is administered at a dose of 1 to 100 mg/kg.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the I-BRD9 is administered at a dose of 5 to 50 mg/kg.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the I-BRD9 is administered at a dose of 10 to 20 mg/kg.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the I-BRD9 is in a form of composition which further comprises pharmaceutically acceptable excipients.

### Claim 6 (depends on 1)

The method according to claim 1, further comprising administering to the subject in need thereof other anti-epileptic drugs.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the I-BRD9 is in an injectable dosage form.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the injectable dosage form is an injection or a powder-injection.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the injectable dosage form is administered by intravenous injection, intraperitoneal injection, subcutaneous injection or intramuscular injection.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the I-BRD9 is administered by gastrointestinal administration.